Sector News

J&J nears diabetes device exit with $2.1 bln LifeScan sale

March 19, 2018
Life sciences

Johnson & Johnson said on Friday it was offered about $2.1 billion for its LifeScan Inc unit, which makes blood glucose monitoring products, by private equity firm Platinum Equity, another step towards exiting the diabetes device market.

Sales at J&J’s diabetes device business, which also includes Animas Corp and Calibra Medical Inc, have been falling since 2012 in a highly competitive market and the company said last January that it was evaluating options for the units.

J&J said in October it would shut down Animas, which makes insulin pumps, after failing to find a buyer. J&J spokeswoman Donna Lorenson said the strategic review of the Calibra division, which sells wearable insulin pumps, is ongoing.

LifeScan, which has headquarters in Chesterbrook, Pennsylvania, and Zug, Switzerland, sells personal blood glucose meters, testing strips, and testing systems. More than 20 million people in 90 countries use its products.

Platinum Equity said in a press release that it is currently consulting with works councils that represent employees. The offer could be finalised by mid-June, unless it is extended, and a deal is anticipated to close by the end of 2018.

The company has 2,400 employees, largely in Europe, China and the United States, Lorenson said.

ANALYSTS SAY PRICE OK

The price for LifeScan, which generated revenue of about $1.5 billion in 2017, was disappointing but fair since the unit had weighed on J&J’s growth for some time, Atlantic Equities analyst Steve Chesney said.

“Obviously expectations were for a higher valuation based on earlier reports, but probably closer to reality given the state of the business,” Chesney said.

Reuters had reported in January that Chinese buyers were interested in paying $3 billion to $4 billion for the companies.

Cowen analyst Joshua Jennings said in a research note that the LifeScan valuation was reasonable given that the business was declining and facing continued pricing pressure.

J&J said it factored the transaction into the 2018 earnings forecast it gave in January.

J&J shares fell 0.4 percent, or 56 cents, to $132.50 in morning trading.

By Arjun Panchadar and Munsif Vengattil

Source: Reuters

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach